

Staphylococcus aureus, Strain Reynolds

Catalog No. NR-45908

For research use only. Not for human use.

Contributor:

Jean C. Lee, Associate Professor of Medicine and Associate Microbiologist, Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Manufacturer:

BEI Resources

Product Description:

Bacteria Classification: *Staphylococcaceae*, *Staphylococcus*

Species: *Staphylococcus aureus*

Strain: Reynolds

NARSA Catalog Number: NRS102

Original Source: *Staphylococcus aureus* (*S. aureus*), strain Reynolds was isolated in 1979 from a human blood culture in North Hollywood, California, USA.¹⁻⁴

Comments: *S. aureus*, strain Reynolds is a capsule-producing methicillin-sensitive *S. aureus* (MSSA) strain. Strain Reynolds was deposited as resistant to penicillin and having spontaneous sulfamethoxazole-resistance; negative for *mecA*; MLST sequence type (ST) 25; eGenomic *spa* type 867, eGenomic *spa* repeats ZGM; Ridom *spa* type t287.² Strain Reynolds is the prototype strain for type 5 capsular polysaccharide. It is believed that capsules produced by these polysaccharides enhance *S. aureus* virulence by impeding phagocytosis as well as promoting abscess formation.⁵ Note: Methicillin is no longer clinically used, however, the terms methicillin-resistant *Staphylococcus aureus* (MRSA) and methicillin-sensitive *Staphylococcus aureus* (MSSA) continue to be used to describe the susceptibility of *S. aureus* strains to the penicillins.

S. aureus is a Gram-positive, cluster-forming coccus that normally inhabits human nasal passages, skin and mucus membranes. It is also a human pathogen and causes a variety of pus-forming infections as well as food-poisoning and toxic shock syndrome. In 1961, two years after the introduction of methicillin, a penicillinase-resistant penicillin, *S. aureus* developed methicillin-resistance due to acquisition of the *mecA* gene. Subsequently, MRSA infections have become widespread in both hospital and community settings.⁶ As compared to MSSA infections, MRSA infections tend to have more complications such as a higher recurrence rate and higher mortality.⁷⁻⁹

Material Provided:

Each vial contains approximately 0.5 mL of bacterial culture in Tryptic Soy broth supplemented with 10% glycerol.

Note: If homogeneity is required for your intended use, please purify prior to initiating work.

Packaging/Storage:

NR-45908 was packaged aseptically in cryovials. The product is provided frozen and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Media:

Brain Heart Infusion broth or Tryptic Soy broth or equivalent
Brain Heart Infusion agar or Tryptic Soy agar with 5% defibrinated sheep blood or equivalent

Incubation:

Temperature: 37°C

Atmosphere: Aerobic

Propagation:

1. Keep vial frozen until ready for use, then thaw.
2. Transfer the entire thawed aliquot into a single tube of broth.
3. Use several drops of the suspension to inoculate an agar slant and/or plate.
4. Incubate the tube, slant and/or plate at 37°C for 18 to 24 hours.

Citation:

Acknowledgment for publications should read "The following reagent was provided by the Network on Antimicrobial Resistance in *Staphylococcus aureus* (NARSA) for distribution by BEI Resources, NIAID, NIH: *Staphylococcus aureus*, Strain Reynolds, NR-45908."

Biosafety Level: 2

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for

informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Karakawa, W. W. and W. F. Vann. "Capsular Polysaccharides of *Staphylococcus aureus*." In J. B., Robbins, J. C. Hill, and J. C. Sadoff (ed.), Seminars in Infectious Disease, Vol. 4. Bacterial Vaccines. New York: Thieme Stratton, Inc., 1982. p. 285-293.
2. NARSA, NRS102
3. Sompolinsky, D., et al. "Encapsulation and Capsular Types in Isolates of *Staphylococcus aureus* from Different Sources and Relationship to Phage Types." J. Clin. Microbiol. 22 (1985): 828-834. PubMed: 2932464.
4. Camussone, C., et al. "Genotypic and Phenotypic Detection of Capsular Polysaccharides in *Staphylococcus aureus* Isolated from Bovine Intramammary Infections in Argentina." Braz. J. Microbiol. 43 (2012): 1010-1014. PubMed: 24031920.
5. O'Riordan, K. and J. C. Lee. "Staphylococcus aureus Capsular Polysaccharides." Clin. Microbiol. Rev. 17 (2004): 218-234. PubMed: 14726462.
6. Deurenberg, R. H. and E. E. Stobberingh. "The Evolution of *Staphylococcus aureus*." Infect. Genet. Evol. 8 (2008): 747-763. PubMed: 18718557.
7. Park, D. A., et al. "Impact of Methicillin-Resistance on Mortality in Children and Neonates with *Staphylococcus aureus* Bacteremia: A Meta-Analysis." Infect. Chemother. 45 (2013): 202-210. PubMed: 24265968.
8. Porto, J. P., et al. "Active Surveillance to Determine the Impact of Methicillin Resistance on Mortality in Patients with Bacteremia and Influences of the use of Antibiotics on the Development of MRSA Infections." Rev. Soc. Bras. Med. Trop. 46 (2013): 713-718. PubMed: 24474012.
9. Inoue, S., et al. "Comparison of Clinical Features and

Outcomes of *Staphylococcus aureus* Vertebral Osteomyelitis Caused by Methicillin-Resistant and Methicillin-Sensitive Strains." SpringerPlus 2 (2013): 283. PubMed: 23853753.

ATCC® is a trademark of the American Type Culture Collection.

